Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1CNS 1

Conditions

Neoplasms 3Solid Tumours 2Multiple Myeloma 2Lymphoma 2Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Neuroblastoma 1Myelodysplastic Syndromes 1Metastatic NUT Carcinoma 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia 1Carcinoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 101Etoposide 60Carboplatin 55Vincristine 51Filgrastim 49Topotecan 44Temozolomide 44Melphalan 44Isotretinoin 44Doxorubicin 44Irinotecan 42Cisplatin 353-Iodobenzylguanidine 34Peripheral Blood Stem Cell Transplantation 31dinutuximab 30Granulocyte Colony-Stimulating Factor 30Radiotherapy 29sargramostim 28Granulocyte-Macrophage Colony-Stimulating Factor 25Busulfan 22Magnetic Resonance Spectroscopy 19aldesleukin 18Thiotepa 18fludarabine 17Interleukin-2 17humanized 3F8 anti-GD2 monoclonal antibody 16etoposide phosphate 16naxitamab 15Ifosfamide 15Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × molibresib × Clear all
NCT01587703 2020-03-16

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers

GlaxoSmithKline

Phase 1 Completed
196 enrolled 78 charts
CNSPlasma cellThoracic

Carcinoma, Multiple Myeloma, Neoplasms, Neuroblastoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡